Add Company
Join Now

Code Biotherapeutics Revenue and Competitors

License our Company Data API

Hatfield, PA USA

Location

$10M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Code Biotherapeutics's estimated annual revenue is currently $3.6M per year.(i)
  • Code Biotherapeutics's estimated revenue per employee is $77,500
  • Code Biotherapeutics's total funding is $10M.

Employee Data

  • Code Biotherapeutics has 46 Employees.(i)
  • Code Biotherapeutics grew their employee count by -8% last year.

Code Biotherapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head Translational MedicineReveal Email/Phone
3
Head, Process Development and Preclinical Production; Co-Founder at Code BioTherapeuticsReveal Email/Phone
4
Head Project ManagementReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
Chief Platform Technologies OfficerReveal Email/Phone
7
Chief Business OfficerReveal Email/Phone
8
Director, CMC Project Management at Code BioTherapeuticsReveal Email/Phone
9
Chief Operating OfficerReveal Email/Phone
10
Preclinical Process Development LeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Code Biotherapeutics?

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne's Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

keywords:N/A

$10M

Total Funding

46

Number of Employees

$3.6M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.4M480%N/A
#2
$3.9M4814%N/A
#3
N/A5216%N/A
#4
$11.7M528%N/A
#5
$13.6M540%N/A